Stocks
Mesoblast LimitedMESO
NASDAQHealthcareBiotechnology$12.31
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing cellular medicines for inflammatory and immune-mediated diseases, including heart failure and chronic low back pain. Its lead product, remestemcel-L, targets steroid-refractory acute graft-versus-host disease, a niche but high-value indication. Investors track MESO for its late-stage pipeline and regulatory milestones in the U.S. and Japan.
52W Range: $11.89-$21.50
Congressional Interest in Mesoblast Limited (MESO)
No congressional trades have been disclosed for Mesoblast Limited (MESO) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading MESO?
No congressional trades found for this stock.